Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions(PEPI)Trial

JAMA: The Journal of the American Medical Association

Volumn 273, Issue 3, 1995, Pages 199-208

  Mebane Sims, Irma L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; FIBRINOGEN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GALLBLADDER DISEASE; HEART DISEASE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYSTERECTOMY; MULTICENTER STUDY; NORMAL HUMAN; OBESITY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HYPERTENSION; THROMBOEMBOLISM;

EID: 77957126077     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.273.3.199     Document Type: Article

References (62)

1. Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Korenman SG, ed. The Menopause: Biological and Clinical Consequences of Ovarian Failure; Evolution and Management. Norwell, Mass: Serono Symposia; 1990:211-224.
2. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991; 20:47-63.
3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med. 1992;117:1016-1037.
4. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987;94:620-635.
5. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Ob- 1992;99:821-828.
6. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in post-menopausal women. Arch Intern Med. 1994;154: 1333-1339.
7. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
8. Tikkanen MJ. Mechanisms of cardiovascular protection by post menopausal hormone replacement therapy. Cardiovasc Risk Factors. 1993;3:138-143.
9. Riedel M, Rafflenbeul W, Lichtlen P. Ovarian sex steroids and atherosclerosis. Clin Invest. 1993; 71:406-412.
10. Gangar KF, Reid BA, Crook D, Hillard TC, Whitehead MI. Oestrogens and atherosclerotic vascular disease: local vascular factors. Baillieres Clin Endocrinol Metab. 1993;7:47-59.
11. Miller VT. Dyslipoproteinemia in women: special considerations. Endocrinol Metab Clin North Am. 1990;19:381-398.
12. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
13. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
14. Rijpkema AH, van der Sanden AA, Ruijis AH. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas. 1990;12:259-285.
15. Goldbourt U, Medalie JH. High density lipoprotein cholesterol and incidence of coronary heart disease: the Israeli Ischemic Heart Disease Study. Am J Epidemiol. 1979;109:296-308.
16. Castelli WP. Cardiovascular disease in women. Am J Obstet Gynecol. 1988;158:1553-1560.
17. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993; 153:2209-2216.
18. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study. Circulation. 1987;75:1102-1109.
19. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski VA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J. 1988; 115:954-963.
20. Tikkanen MJ, Kuusi T, Nikkila EA, Sipinen S. Post-menopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins: a review. Maturitas. 1986;8:7-17.
21. Newnham HH. Oestrogens and atherosclerotic vascular disease: lipid factors. Baillieres Clin Endocrinol Metab. 1993;7:61-93.
22. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
23. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis. 1990;10:531-534.
24. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 1994; 84:987-995.
25. The PEPI Investigators. The Postmenopausal Estrogen/Progestins Interventions Trial: rationale, design, and conduct. Control Clin Trials. In press.
26. The PEPI Investigators. Baseline characteristics of women in the Postmenopausal Estrogen/ Progestins Interventions Trial. Control Clin Trials. In press.
27. The PEPI Investigators. The recruitment of healthy postmenopausal women for a multicenter trial: the Postmenopausal Estrogen/Progestins Interventions(PEPI)experience. Control Clin Trials. In press.
28. The PEPI Investigators. The Postmenopausal Estrogen/Progestins Interventions Trial: physical and laboratory measurements. Control Clin Trials. In press.
29. Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab. 1991;73:373-379.
30. Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156:66-71.
31. Hypertension Detection and Follow-up Program Cooperative Group. Variability of blood pressure and the results of screening in the Hypertension Detection and Follow-up Program. J Chronic Dis. 1978;31:651-667.
32. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 1986; 129:101-123.
33. Bachorik PS, Albers JJ. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 1986;129:78-100.
34. Hainline A, Karon J, Lippel K, eds. Manual of Laboratory Operations:Lipid Research Clinics Program, Lipid and Lipoprotein Analysis. 2nd ed. Washington, DC: National Institutes of Health, US Dept of Health and Human Services; 1982.
35. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24.
36. Morgan CR, Laarow A. Immunoassay of insulin— two antibody system: plasma levels of normal, sub-diabetic and diabetic rats. Diabetes. 1963;12:115-126.
37. Clauss A. Gerinnungs physiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
38. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
39. SAS Institute Inc. Changes and enhancements. In: SAS Technical Report P-229, SAS/SAT Software, Release 6.07. Cary, NC: SAS Institute Inc; 1992.
40. Edwards AL. Experimental Design in Psychological Research. 5th ed. New York, NY: Harper & Row Publishers Inc; 1985.
41. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32-47.
42. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
43. Walsh BW, Sacks FM. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest. 1993;91:2126-2132.
44. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 1994;5:236-240.
45. Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglycleridemic women. J Lab Clin Med. 1994;123:59-64.
46. Mashchak CA, Lobo RA, Donozo-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144:511-518.
47. Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation. 1987;76:753-758.
48. Mashchak CA, Lobo RA. Estrogen replacement therapy and hypertension. J Reprod Med. 1985;30: 805-810.
49. Barrett-Connor E. Putative complications of estrogen replacement therapy: hypertension, diabetes, thrombophlebitis, and gallstones. In: Korenman SG, ed. The Menopause: Biological and Clinical Consequences of Ovarian Failure; Evolution and Management. Norwell, Mass: Serono Symposia; 1990:199-209.
50. Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens. 1994;8:491-494.
51. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab. 1992;74:1396-1400.
52. Stevenson JC, Proudler AJ, Walton C, Godsland IF. HRT mechanisms of action: carbohydrates. Int J Fertil Menopausal Stud. 1994;39:50-55.
53. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137: 959-965.
54. Godsland IF, Gangar KF, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 1993; 42:846-853.
55. De Cleyn K, Buytaert P, Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas. 1989;11:235-242.
56. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol. 1992;2:445-455.
57. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and the risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
58. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332-1334.
59. Rosano GM, Sarrell PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 1993;342:133-136.
60. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994;90: 786-791.
61. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312-317.
62. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14:32-38.